Prelude Therapeutics Inc (PRLD) stock news · rev $12.1M
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
This PRLD news page leads with what Prelude Therapeutics Inc filed — not a scraped headline mill.
No cached 8-K sentence for PRLD yet. We will not pad this page with generic market recap.
Latest reported PRLD revenue for 2025-12-31 was $12.1M. Net income was -$99.5M. Revenue was up 73.4% from 2024-12-31 to 2025-12-31. PRLD currently screens at market cap $346.5M.
EDGAR remains the official archive. Lician caches the exhibit so you can read what changed without a wire story.
Not investment advice. For the model open the PRLD stock page; for the tape open the quote page.
PRLD stock news FAQ
What are PRLD's latest revenue and net income?
Latest cached Prelude Therapeutics Inc (PRLD) revenue for Dec 31, 2025 was $12.1M. Net income was -$99.5M. Statements: https://lician.com/financials/prld
How did PRLD revenue change from the prior cached period?
Cached Prelude Therapeutics Inc (PRLD) revenue was up 73.4% from $7.0M (Dec 31, 2024) to $12.1M (Dec 31, 2025). Statements: https://lician.com/financials/prld
What is PRLD's market cap?
Prelude Therapeutics Inc (PRLD) market cap is $346.5M on the latest cached fundamentals snapshot.
What kind of company is PRLD?
Prelude Therapeutics Inc (PRLD) is a biotechnology company listed on NASDAQ.
Where is PRLD stock news listed?
Cached stock news for Prelude Therapeutics Inc (PRLD) is listed at https://lician.com/news/prld. Filings: https://lician.com/sec/prld
Not investment advice.